FY2025 · ended Dec 31, 2025 · Revenue $1.18B, -0.4% YoY · Filed Feb 26, 2026
Trulieve Cannabis Corp. (TRLV) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 billion and a net loss of $122.2 million. Free cash flow was $228.6 million. As of Sep 30, 2026 it held $326.7 million in cash and investments and $368.4 million in total debt.
Revenue (TTM)
$1.08B
-9.1% vs year-ago TTM
Net income (TTM)
$-446.60M
-218.5% vs year-ago TTM
Operating cash flow (TTM)
$242.48M
-0.7% vs year-ago TTM
Free cash flow (TTM)
$188.18M
+27.0% vs year-ago TTM
EPS (TTM)
$-2.32
-231.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
192.31M
+0.7% vs prior year
Net cash
$-41.76M
as of Sep 30, 2026
Operating margin
-25.6%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TRLV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Tallahassee, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1754195
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.2B | $931.9M |
| Operating income | $143.5M | $97.8M | -$221.6M | $50.2M | $204.1M |
| Net income | -$122.2M | -$160.6M | -$533.1M | -$252.7M | $17.4M |
| Diluted EPS | -$0.58 | -$0.79 | -$2.28 | -$0.95 | $0.21 |
| Operating cash flow | $272.8M | $271.5M | $201.8M | $23.1M | $12.9M |
| Free cash flow | $228.6M | $148.9M | $161.6M | -$141.7M | -$263.0M |
| Total assets | $2.7B | $2.9B | $2.7B | $3.4B | $3.4B |
| Total liabilities | $1.6B | $1.6B | $1.3B | $1.5B | $1.3B |
| Stockholders' equity | $1.1B | $1.2B | $1.4B | $1.9B | $2.1B |
| Cash and investments | $255.5M | $299.2M | $201.4M | $207.2M | $226.6M |
| Total debt | $332.5M | $571.7M | $534.8M | $739.1M | $666.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 5, 2026 | Aug 5, 2026 |
All 416 Trulieve Cannabis Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.